RxDoctor Payments Data

Carolyn Ferguson, APRN

Nurse Practitioner · Fairbury, NENPI 1942653415

Payments from drug & device makers

$516in general payments, 2019–2025

Across 30 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$203
  • Abbott$121
  • Lilly USA, LLC$45
  • Johnson & Johnson$34
  • Boehringer Ingelheim$30
  • Bayer$29
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$516100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$516 in reported general payments places this provider in the 60th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$19,744
Medicare patients
117
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$38,231
EliquisApixaban17$26,033
MounjaroTirzepatide22$22,761
XareltoRivaroxaban17$15,493
Tresiba Flextouch U-200Insulin Degludec12$6,970
VascepaIcosapent Ethyl11$4,049
Varenicline Tartrate13$3,324
Atorvastatin Calcium313$3,256
Albuterol Sulfate HfaAlbuterol Sulfate96$2,648
Rosuvastatin Calcium72$2,232
Duloxetine Hcl52$2,065
Levothyroxine Sodium185$1,726
Omeprazole132$1,618
Gabapentin109$1,452
Pantoprazole Sodium72$1,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$38,23134 claims
Lilly USA, LLCMounjaro$45$22,76122 claims
Johnson & JohnsonXarelto$34$15,49317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Fairbury

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →